Navigation Links
Milk thistle extract stops lung cancer in mice

Tissue with wound-like conditions allows tumors to grow and spread. In mouse lung cancer cells, treatment with silibinin, a major component of milk thistle, removed the molecular billboards that signal these wound-like conditions and so stopped the spread of these lung cancers, according to a recent study published in the journal Molecular Carcinogenesis.

Though the natural extract has been used for more than 2,000 years, mostly to treat disorders of the liver and gallbladder, this is one of the first carefully controlled and reported studies to find benefit.

Here is how it works:

Basically, in a cell there can be a chain of signals, one leading to the next, to the next, and eventually to an end product. And so if you would like to eliminate an end product, you may look to break a link in the signaling chain that leads to it. The end products COX2 and iNOS are enzymes involved with the inflammatory response to perceived wounds both can aid tumor growth. Far upstream in the signaling chain that leads to these unwanted enzymes are STAT1 and STAT3. These transcription factors allow the blueprint of DNA to bind with proteins that continue the signal cascade, eventually leading to the production of harmful COX2 and iNOS.

Stop STAT1 and STAT3 and you break the chain that leads to COX2 and iNOS and the growth of lung tumors along with them.

"This relatively nontoxic substance a derivative of milk thistle, called silibinin was able to inhibit the upstream signals that lead to the expression of COX2 and iNOS," says Alpna Tyagi, PhD, investigator at the University of Colorado Cancer Center and member of the Agarwal Lab at the Skaggs School of Pharmacy and Pharmaceutical Sciences.

In addition, Tyagi and collaborators compared the effects of silibinin to drugs currently in clinical trials for lung cancer. Would drugs that target other signaling pathways other linked chains similarly cut into the production of COX2 and iNOS?

It turned out that inhibiting the chains of JAK1/2 and MEK in combination and also inhibiting the signaling pathways of EGFR and NF-kB in combination blocked the ability of STAT1 and STAT3 to trap the energy they needed to eventually signal COX2 and iNOS production.

Compared to these multi-million dollar drugs, naturally-occurring silibinin blocked not only the expression of COX2 and iNOS, but also the migration of existing lung cancer cells.

"What we showed is that STAT1 and STAT3 may be promising therapeutic targets in the treatment of lung cancer, no matter how you target them," Tyagi says. "And also that naturally-derived products like silibinin may be as effective as today's best treatments."


Contact: Garth Sundem
University of Colorado Denver

Related medicine news :

1. Warning Over Dangers of Used Racking Issued By Thistle Systems
2. Influence of pulp extraction technique on DPSCs quality and quantity
3. Researchers develop successful method for extracting and archiving patient radiation dose info
4. Cashew seed extract an effective anti-diabetic
5. Abbey Color Inc. and Mexicana de Extractos International, S.A. de C.V. Announce Joint Venture Abbymex
6. Sunwin International & WILD Flavors Receive GRAS Letters of No Objection from FDA Validating Safety of Multiple Sunwin Stevia Extracts
7. Green Tea Extract May Delay or Prevent Alzheimers
8. Less Is More with the Innovation of Avemar(R) Fermented Wheat Germ Extract
9. Bitter Melon Extract May Slow, Stop Breast Cancer
10. Bitter melon extract decreased breast cancer cell growth
11. Bitter melon extract attacks breast cancer cells
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... GRAND RAPIDS, Mich. (PRWEB) , ... October 12, ... ... OnSite Wellness, has been named one of Michigan’s 2017 Best and Brightest in ... Best and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
Breaking Medicine Technology: